Bio-behavioral Survey of Transgender Men and Transgender Women in Ukraine

Survey Protocol Version: 0.1

[Insert Date of Submission to IRB]

Kyiv, Ukraine

TABLE OF CONTENTS

INVESTIGATORS AND INSTITUTIONAL AFFILIATIONS

Chris Obermeyer, BS, M.Ed
Email: chris.a.obermeyer@gmail.com

Anna Meteliuk, MS, MPA
Email: meteliuk@gmail.com

Igor Medvid
Email: medvid@hplgbt.org

Ihor Kuzin, MD, MPH
Email: i.kuzin@ukraids.gov.ua

Field Implementing Organization:

FUNDING SOURCE

This study is sponsored by the Global Fund

ABBREVIATIONS, ACRONYMS, AND DEFINITIONS

AE (adverse event)

BBS (bio-behavioral survey) -study with biological and behavioral components

Behavioral component -portion of the study that asks about participant behaviors

Biological component -portion of the study that tests participants for HIV, Hepatitis B/C, Syphilis and includes pre/post test counseling

CSW (commercial sex worker)

DBS (dry blood sample)

Field staff- staff hired by the implementation partner

MSM (men who have sex with men) -men who have sexual interactions with other men

NGO (non-governmental organization) -an organization that provides community services outside or alongside those performed by the government

PHC (Public Health Center)

PWID (people who inject drugs)

RDS (respondent driven sampling) -survey recruitment methodology where seeds are chosen given specific criteria, participate in the study, and then recruit other respondents who might qualify for participation using recruitment coupons

Recruiter-a study participant who recruits other potential participants using coupons after they have participated in the study themselves

Research team- authors of the study

Seeds -participants who are part of the target group who are chosen given specific criteria and who are the start of recruitment chains

TW (transgender woman) -someone whose birth certificate says male but identifies as a woman/female

TM (transgender man) -someone whose birth certificate says female but identifies as a man/male

Transgender person - someone whose gender identity is different than that typically associated with the sex on their birth certificate

ABSTRACT

This is a bio-behavioral survey (BBS) of transgender men (TM) and transgender women (TW) in Ukraine. A convenience sampling of 100 TM will be recruited in Kyiv City/Kyivska Oblast while respondent driven sampling (RDS) will be used to recruit 900 TW in Kharkivska Oblast, Kyiv City/Kyivska Oblast, and Odeska Oblast. Participants will give consent to take part in all components of the study.

The study includes:

- Eligibility and Informed Consent
- Four face-to-face interview sections about behavioral practices;
- Computer assisted self-interview about behavioral practices;
- Rapid testing for HIV, hepatitis B, hepatitis C, and syphilis testing and pre/post test counseling
- Returning of test results to study participants
- Referral to HIV/AIDS centers or clinics for care and support services for those testing positive for HIV, hepatitis B, hepatitis C, and syphilis
- Dry blood sample (DBS) for HIV recency testing and viral load for those testing positive for HIV

The objectives of the study are to:

- Estimate the prevalence/incidence of HIV, hepatitis B, hepatitis C, and syphilis;
- Estimate prevalence of related behavioral practices;
- Estimate utilization of prevention and treatment services within these populations;
- Estimate the population size of TW
- Estimate UNAIDS 90-90-90 treatment cascades

All respondents will give consent to participate in the study. Study data will highlight the health needs of transgender people in Ukraine and results will be disseminated to national and international stakeholders to guide future health programs for the target population.

INTRODUCTION

BACKGROUND AND JUSTIFICATION

While there are an estimated 25 million transgender people globally, only 30 countries have reported estimates listed on UNAIDS' website. Despite transgender people being 49 times more likely to be living with HIV than the general population, only 20 countries have reported estimates of HIV prevalence which range from 0.4% in Fiji to 24.8% in Indonesia. Globally, an estimated 19% of TW are living with HIV with little reliable research regarding HIV prevalence among TM due to small sample sizes. The largest study including TM, which was conducted in the United States indicates that HIV prevalence among TM is also higher than the general population. An in-depth search for peer reviewed articles on PubMed indicated there are zero peer-reviewed studies published about transgender people and HIV in any of the post-Soviet states. This study will be the first of its kind in the region.

An estimated 241 000 people are living with HIV in Ukraine. People who inject drugs (PWID), commercial sex workers (CSW), and men who have sex with men (MSM) have all been identified as key populations at increased risk for HIV and have been the targets of bio-behavioral surveys in Ukraine for more than a decade. While some TW have been surveyed as part of past MSM IBBS, it is necessary to survey TW separately to gather representative samples in order to estimate the size of the population and better understand behavioral and biological prevalences within this population specifically. Likewise, since little is known about TM globally, a convenience sampling of TM is needed to gain insight into behavioral practices and biological data to understand if pursuing a larger study in Ukraine is needed and possible.

STUDY OBJECTIVES

- Estimate the prevalence/incidence of HIV, hepatitis B, hepatitis C, and syphilis;
- Estimate prevalence of related behavioral practices;
- Estimate utilization of prevention and treatment services within these populations;
- Estimate the population size of TW
- Estimate UNAIDS 90-90-90 treatment cascades

STUDY DESIGN AND METHODOLOGY

Cross-sectional study data will be collected from TW through respondent-driven sampling (RDS) while a convenience sampling will be collected from TM.

The study will have two components; behavioral and biological. Consent will be requested for both parts separately with the behavioral component being required for participation.

Behavioral data will be collected using four face-to-face interview sections with the remaining sections being completed using computer-assisted self-interviews (CASI).

Biological data will be collected using rapid tests for HIV, hepatitis B, hepatitis C, syphilis. Those who test positive for HIV will take a second rapid test of a different brand for confirmation and a third from a different brand if there is a discrepancy between the first two. Participants confirmed positive using the rapid tests will then be asked to give a DBS determine recency of HIV infection and to measure viral load.

SURVEY POPULATION

TW and TM will participate in the study. 300 TM will be surveyed in each of the study areas including; Kharkivska Oblast, Kyiv City/Kyivska Oblast, and Odeska Oblast while 100 TM will be surveyed in Kyiv City/Kyivska Oblast only.

Given significant evidence that TW are more likely to be living with HIV and indications that TM also have a higher prevalence of HIV, this study will only include transgender people who are TW or TM.

PARTICIPANT INCLUSION CRITERIA

INCLUSION CRITERIA	VERIFICATION METHOD(S)
14 years of age or older at time of participation	Self-reported, visual control by field staff
Live in study area	Self-reported
Consent to behavioral component	Verbal consent
Gender identity that does not match the sex on their birth certificate	Self-reported
Having ever had anal or vaginal sex or injected drugs/hormones with a needle after someone else has injected drugs/hormones	Self-reported

PARTICIPANT EXCLUSION CRITERIA

EXCLUSION CRITERIA	VERIFICATION METHOD(S)
13 years of age or younger at time of participation	Self-reported, visual control by field staff
Previous participation in this study	Self-reported, visual control by field staff
Alcohol or drug intoxication	Visual control by field staff

SAMPLING METHODS

RESPONDENT DRIVEN SAMPLING OF TW

TW will be recruited to participate in the study using RDS in order to recruit a representative sampling of TW in the three study areas and produce a size estimation of TW. RDS has been shown to be an effective method to sample hard-to reach populations and produce quality estimates. RDS begins with the selection of “seeds” who are part of the target population and well connected to other members of the target population. Seeds are asked to participate in the study and upon completion of the study are compensated and given a set number of recruitment coupons to recruit other members of the target population to participate in the study. If these recruits are eligible and complete the survey, the seed is compensated for each recruit. These secondary participants are compensated for their participation and then given a set number of recruitment coupons to recruit additional members of the target population. Secondary participants are then compensated for target population members who are eligible and participate. This process continues until both the sample size is reached and recruitment chains converge on prevalence of key behavioral markers. Since data is being collected using tablets it will be monitored daily to ensure successful recruitment.

RDS Analyst software will utilize reported network sizes and similarities in characteristics among these networks to analyze the data and determine confidence intervals and prevalence estimates. To do this successfully, recruitment coupons will be individually numbered and tracked to link participants within the recruitment chains.

CONVENIENCE SAMPLING OF TRANSGENDER MEN

A convenience sampling of TM will be recruited to participate in the study through NGOs and open peer referrals. This methodology has been chosen because it is expected that the population of TM in Ukraine would make recruiting a representative sample size impossible.

LOCATIONS

TW from three oblasts (Kharkivska Oblast, Kyiv City/Kyivska Oblast, and Odeska Oblast) will participate in the study. The survey itself will take place in the oblast centers (Kharkiv, Kyiv, and Odesa respectively) with the entire oblast acting as the eligibility areas to ensure sample sizes can be met. These areas were chosen due to their large populations and the presence of at least one non-governmental organization (NGO) with targeted programs and services directly for people who are transgender.
TM from Kyiv City/Kyivska Oblast will participate in the study. The survey itself will take place in Kyiv City due to its large population and presence of multiple NGOs which can promote the study through their networks.

SAMPLE SIZE CALCULATION OF TW

RECRUITMENT AND ENROLLMENT

RECRUITMENT OF TW

Recruitment of TW through RDS will be started by seeds and continue through recruited participants. Approximately 4 seeds will be chosen for each study area from information gathered from key informants during the formative assessment. All seeds must be willing to take the survey and recruit peers. If they refuse to recruit peers, new seeds can be chosen. Additional seeds may be added if recruitment is slower than necessary or if recruitment chains end. Additional criteria should be decided upon during the formative assessment to determine if there is sufficient interaction between TW of different ages and risk behaviors (sex work, drug use, etc.). After seeds take part in the study themselves, they will be given 3 coupons (see appendix 1) to recruit secondary participants following the recruitment instructions (see appendix 2). Once seeds recruit secondary participants using uniquely identified coupons, secondary participants will also be asked to recruit using the 3 recruitment coupons they will be given. If recruitment moves too quickly in some areas as monitored regularly, participants may be given 2 coupons instead of 3.

RECRUITMENT OF TM

Recruitment of TM through convenience sampling will be conducted in collaboration with NGOs working with TM in Kyiv.

ENROLLMENT

Coupons codes will be recorded on the eligibility form and potential participants will be asked questions to develop their participant ID and eligibility based on the inclusion/exclusion criteria through a face-to-face questionnaire (see appendix 3). If found eligible, consent will be requested verbally. If consent is given, the answers to the eligibility questions will be entered into the tablet to confirm eligibility and the survey will commence following prompts on the tablet.

DATA COLLECTION, MANAGEMENT, MONITORING, AND ANALYSIS

DATA COLLECTION PROCEDURES

Activity	Person Responsible	Timing
Validation of recruitment coupon		
Screening of potential participant		
Reading of and confirmation of informed consent		
Questionnaire		
Pre-test counseling		
Rapid testing for HIV, hepatitis B, hepatitis C, and syphilis		
2nd HIV rapid test (for those testing positive on 1st rapid test)		
3rd HIV rapid test (for those with discrepant results on rapid test 1 and 2)		
DBS preparation (for those who are HIV positive)		

Returning test results		
Post-test counseling and referral to services		
Linkage to HIV/AIDS Center (for those who test positive)		
Compensation for participation		
Instructions for peer recruitment		
Recruitment of peers		
Participation of peers		
Secondary compensation		

BEHAVIORAL DATA COLLECTION PROCEDURES

The eligibility portion of the study will be entered into the tablets from the eligibility form. The following four sections will be conducted face-to-face with the interviewer following prompts from the tablet, as recommended by the WHO *Biobehavioural Survey Guidelines for Populations at Risk for HIV*. The remaining sections will be conducted through a computer-assisted self interview using RedCap data collection software with the participant entering answers into the tablets themselves.

The questionnaire (see appendix 6) was originally developed in English and was translated into Russian by qualified translators before being piloted during the formative assessment and modified utilizing this feedback.

It was developed using WHO recommendations and includes nearly all core questions for transgender populations as well as most core questions from surveys for people who inject drugs and those who engage in sex work. Additional questions were created and included using input from the authors and the formative assessment. The questions from WHO will enable the completion of standardized reporting and comparison across key populations.

BIOLOGICAL SPECIMEN COLLECTION PROCEDURES

Consent for the biological component will be seperate from consent for the behavioral component and will not be a requirement for participation in the behavioral component. The biological component will take place after the behavioral component is completed. The biological component has three main parts: pre-test counseling; testing; and post-test counseling and linkage to services.

PRE-TEST COUNSELING

Following the Ukrainian National VCT Protocol, upon completion of the behavioral component, those who consented to testing will receive pre-test counseling. The counseling will include information about:

- transmission of HIV, hepatitis B, hepatitis C, and syphilis
- sexual and drug injection related risk behaviors
- prevention of HIV, hepatitis B, hepatitis C, and syphilis
- treatment of HIV, hepatitis B, hepatitis C, and syphilis and
- how to interpret test results

Upon completion of the pre-test counseling, those who consent will be tested for HIV, hepatitis B, hepatitis C, and syphilis

TESTING

Rapid tests will be collected for HIV, hepatitis B, hepatitis C, and syphilis following standard operating procedures (see appendix 13). Those who test positive for HIV will be confirmed using a second HIV rapid test from a second manufacturer. In the event of the two rapid tests having different results, a third rapid test, from a third manufacturer will be utilized.

Those testing positive will have a dried blood sample stored for recency testing and viral load calculations.

Testing results will be recorded on the Testing Results Form (see appendix 7)

POST-TEST COUNSELING

Following the Ukrainian National VCT Protocol, upon completion of the testing, participants will receive post-test counseling. Results regarding each of the rapid tests will be provided and explained to the participants. Those who test positive for hepatitis B, hepatitis C, and/or syphilis will be informed where they can receive confirmatory testing and treatment. Those who test positive for HIV and confirmed with a second or third rapid test will be linked to the local HIV/AIDS Center by the medical worker. Those who test positive will also be asked if they would like to be linked with local non-governmental organizations which provide counseling and case management services. All participants will be given information in writing about local testing, legal, counseling, and other support services.

DATA MANAGEMENT AND MONITORING

There are five main data collection items:

1. Recruitment Coupon
2. Eligibility Form
3. Informed Consent Form
4. Survey Instrument
5. Testing Results Form

The recruitment coupon will have a unique identifier to link the participant to their recruiter. Upon completion of the eligibility form, the participant ID will be created and will be indicated on all forms and the survey instrument to link them together. This participant ID will not contain information that would make it possible to identify the participant.

Data from forms 1, 2, 3, and 5 will be checked for completeness, verified, and entered into a password protected Excel document and sent to the research team weekly. Hard copies will be kept in locked cabinets at the sites and sent to the research team in sealed packages at the end of each month. Upon receipt of the hard copies, the research team is responsible for keeping them in locked cabinets until data analysis is completed.

The survey instrument will be on tablets using RedCap. Data will automatically be uploaded upon completion of each survey. Individual study sites will only have access to enter data, not to review or edit it. Only the research team will have access to data collected using the survey instrument during collection. RedCap stores the data in protected servers that are HIPAA compliant. Data will be backed up on a daily basis by the research team.

The research team will be responsible for regular monitoring of the independent chains in each region for convergence should it be necessary to change the rate of recruitment or stop it altogether.

The Public Health Center (PHC) will be the data owner and will store data sets and monitoring files for at least ten years. Prior to completion of the study, the PHC will consider how to make datasets available for external investigators.

DATA ANALYSIS

Data will be analyzed in accordance with the tables found on pages 460-514 of the *Biobehavioural Survey Guidelines For Populations At Risk For HIV Supplemental Materials* and in alignment with UNAIDS reporting indicators (see appendix 14).

Data analysis plan, including statistical methodology and planned tables and figures
Data / information management and analysis software
Measurement / estimation and adjustment methods
Limitations of survey (including potential bias in data collection, measurement, analysis)

FORMATIVE ASSESSMENT PROTOCOL

Formative assessments will be conducted in each of the three study locations. The main goals of the formative assessment are:

- Determine seed selection criteria for the RDS sampling of TW
- Determine study sites for RDS sampling of TW
- Improve the survey instrument

Changes to the protocol and survey instrument will be made following the formative assessment and the protocol will be resubmitted to the IRB for review and approval. The formative assessment has two parts; key informant interviews for the RDS sampling of TW and survey piloting for both groups.

KEY INFORMANT INTERVIEWS FOR RDS SAMPLING OF TW

In each of the study areas, key informant interviews will be conducted by field staff. In each study area, key informants must include at least:

- One community representative
- One healthcare working with TW and
- One social worker/outreach worker working with TW

Verbal consent will be requested from each key informant (see appendix 8) and the interviewer will take notes with no personal identifiable information. Using this information, approximately 4 seeds will be chosen per study area through direct or indirect referrals by key informants. Additional seeds may be added after data collection begins to increase the speed of recruitment.

Data collected during the formative interviews will also be used to select the study sites. Study sites will be chosen based on the following criteria:

- Convenience for potential participants
- Comfort for potential participants
- Space for screening, the behavioral component, and the biological components

SURVEY PILOTING

Piloting of the survey instrument after informed consent (see appendix 9) will take place in Kyiv to ensure potential participants will understand the questions and answer choices and to ensure acceptable timing of the behavioral component of the study. All forms to be used in actual implementation, including consent forms, will be utilized to ensure the process is adequate. The field staff will conduct the piloting of the survey and will record any issues. If changes are made, the protocol and survey will be updated and submitted again for IRB review and approval.

TW and TM will be selected for piloting the survey with the assistance of NGOs and community representatives. All pilot participants must meet the eligibility criteria for study participation in order to participate in piloting.

TW piloting the survey must include at least:

- One TW who does not engage in sex work or inject drugs

- One TW who engages in sex work but does not inject drugs
- One TW who does not engage in sex work but does inject drugs
- One TW who engages in sex work and injects drugs

Due to expected challenges in recruiting TM, criteria for TM piloting the survey may need modification but field staff will attempt to recruit at least:

- One TM who does not engage in sex work or inject drugs
- One TM who engages in sex work but does not inject drugs
- One TM who does not engage in sex work but does inject drugs
- One TM who engages in sex work and injects drugs

TIMELINE

Activity	DEC 2017	JAN 2018	FEB 2018	MAR 2018	APR 2018	MAY 2018	JUN 2018	JUL 2018	AUG 2018	SEP 2018	OCT 2018	NOV 2018	DEC 2018	JAN 2019	FEB 2019	MAR 2018
Initial Survey and Protocol Dev.	■	■	■	■	■											
Translation of Survey						■										
Translation of Protocol						■										
Tender for Procurement						■										
Submission for IRB Approval						■										
Formative Research							■									
Piloting of Survey							■									
Finalization of Survey								■								
Trainings for Field Personnel									■							
Data Collection										■	■	■	■			
Data Cleaning														■		
Report on National Indicators															■	
Results Dissemination																■

ETHICAL CONSIDERATIONS

All investigators have current certification in research ethics. The study protocol, questionnaire, and all forms will be approved by the IRB at the PHC.

CONSENT

Before inclusion into the study, all eligible participants will be asked to give verbal informed consent (see appendixes 4 and 5). The consent form will be read aloud to eligible participants and any questions eligible participants have about the study will be answered. They will be informed that their participation in voluntary and they can withdraw their consent and stop participation in the study at any time. Refusal to participate or withdrawal from the study will not affect their access to health facilities or HIV-related care and treatment. They will be informed that all information in the study is confidential and no personally identifiable information will be reported. They will be informed of potential risks and benefits of the study and a copy of the informed consent form will be given to them.

POTENTIAL RISKS

Participants will be asked to undergo testing for HIV, hepatitis B, hepatitis C, and syphilis and provide information about drug use and sexual behaviors. Drawing blood for the rapid tests and DBS involves minimal risk, including localized tissue trauma and infection. Questions may make some participants feel discomfort. Reporting of test results may also make some feel distressed. Participation in HIV prevention or HIV care and treatment programs is not associated with any punitive or social risks aside from stigma attached to being transgender, using drugs, or engaging in sex work. This study does not increase the stigma associated with these identities or behaviors. Although every effort will be made to keep participant information confidential, complete confidentiality cannot be guaranteed.

PROTECTION AGAINST RISKS

To minimize possibilities of localized trauma and infection, the tests for HIV, hepatitis B, hepatitis C, and syphilis will be conducted by trained medical staff.

During the informed consent, participants will be informed that participation is voluntary and anonymous and they can withdraw at any time. They will be informed that they do not have to share their name or any other personal information they feel uncomfortable sharing. Questions on the behavioral component, aside from the eligibility questions, are optional and participants can refuse to answer any questions they feel uncomfortable answering.

Testing and interviewing will take place privately between trained field staff and the participant in accordance with HIV testing and counseling guidelines. Only staff trained in HIV pre-test and post-test counseling will conduct these portions of the study. All participants will be provided with a list of community resources should they seek additional counseling or support in addition to linkages to HIV/AIDS Centers for confirmatory testing for those testing positive for HIV.

Participants will receive names and contacts for those involved in the study and will be encouraged to contact anyone on the list if they have questions, comments, or concerns regarding the study. They will also be asked to contact someone on the research team if they feel they have suffered in any way through their participation in the study.

PROTECTION OF CONFIDENTIAL INFORMATION

All field staff will be trained on how to protect the confidential information of participants and all staff will sign agreements binding them to strict confidentiality (see appendix 10). Participants names will never be recorded and all forms will only contain participant IDs. Data collected through tablets will be saved on RedCap’s HIPAA compliant servers and backed up daily by the research team into a password protected document.

IDENTIFYING, MANAGING, AND REPORTING ADVERSE EVENTS

All adverse events (AE) must be reported within 24 hours using the AE form (see appendix 11) to the research team. Within 24 hours of receipt of the AE form, the research team must develop a verbal or written action plan to address the event and serious events must be reported to the IRB. The research team is responsible for the reporting of serious AE to the IRB.

EMERGENCY CARE

It is not expected that any emergency care will be necessary as a result of this study. If emergency care is needed, the field staff will attempt to locate immediate care for participants.

PROTOCOL DEVIATIONS

Protocol deviations will be reported within 24 hours using the protocol deviation form (see appendix 12) to the the research team. Serious deviations from the protocol must be reported to the IRB. The research team is responsible for the reporting of serious deviations to the IRB.

POTENTIAL BENEFITS

Participants will have no privileges to treatment if found they are found to be positive for HIV, hepatitis B, hepatitis C, and/or syphilis as a result of their participation in the study however they will receive assistance in linkage to care at the HIV/AIDS Center. All participants will receive information about community resources that they may wish to utilize.

COMPENSATION

TW will receive the Ukrainian hryvnia equivalent of $6 for their own participation in the study and the Ukrainian hryvnia equivalent of $3 for each (maximum 3) eligible participant they recruit who also participates in the study.

TM will receive the Ukrainian hryvnia equivalent of $6 for their own participation in the study.

Compensation will be provided after they participate and again after their participant recruitment window has closed.

AGE OF RESPONDENTS

The study target participants who are 14 and older. According to Ukrainian legislation (the Law of Ukraine “On Childhood Protection”) a child is a person under 18 years old (legal age), unless according to the legislation applied to him/her legal age is not gained before.

Paragraph 2.18 of the Code of Sociologist’s Professional Ethics defines that: “2.18. When conducting research with children, a sociologist must receive permission from the child’s parents or a guardian. A sociologist does not need permission from the child’s parents or a guardian when: 1) a survey will have minimal effects on participants; 2) a survey cannot be implemented if such a permission is received; 3) permission from parents or a guardian is not necessary for child protection (for example, from parents deprived of parental rights)”

Since the study has minimal effects on participants and the study could not be implemented if permission is received from a parent/guardian, participant 14-17 years old will be asked for consent themselves. Ukrainian law also guarantees children 14-17 years old access to HIV testing services without parental consent.

Field staff will be trained how to work with children. The referral list given to all participants will also include referrals to services for children who are victims of abuse or exploitation.

NOTIFICATION, REPORTING AND OTHER DISSEMINATION OF STUDY RESULTS

Dissemination of study results will follow data sharing and clearance procedures of the PHC. They will be disseminated through presentations and publications, including peer-reviewed journals and other publications to policy makers, organizations, and the public as soon as possible. They will be used to guide program planning for HIV prevention, treatment, and support services.

The field staff will produce reports on the technical and logistical aspect of study implementation and on the national HIV response indicators as well as those to be reported to UNAIDS.

All presentations and publications will follow procedures of the PHC.

REFERENCES

APPENDIX MATERIALS

APPENDIX 1: RECRUITMENT COUPON FOR RDS OF TW

Coupon Number: _____

Dear Participant,

Please bring this coupon with you to participate in a study related to health issues. If you meet eligibility criteria, you will be able to participate in the study and receive compensation.

This coupon cannot be accepted if: the study has already achieved the maximum number of participants, the coupon is torn, fabricated or unreadable, or the coupon owner has already participated in the study.

Your participation is voluntary and anonymous.

If you wish to participate, please come to {insert address} as soon as possible on {enter days of week of study} from {insert start time} until {insert end time}.

If you want more information about the study you can call {insert phone number}.

Coupon Number: _____

Dear Participant,

Please bring this coupon with you to participate in a study related to health issues. If you meet eligibility criteria, you will be able to participate in the study and receive compensation.

This coupon cannot be accepted if: the study has already achieved the maximum number of participants, the coupon is torn, fabricated or unreadable, or the coupon owner has already participated in the study.

Your participation is voluntary and anonymous.

If you wish to participate, please come to {insert address} as soon as possible on {enter days of week of study} from {insert start time} until {insert end time}.

If you want more information about the study you can call {insert phone number}.

Coupon Number: _____

Dear Participant,

Please bring this coupon with you to participate in a study related to health issues. If you meet eligibility criteria, you will be able to participate in the study and receive compensation.

This coupon cannot be accepted if: the study has already achieved the maximum number of participants, the coupon is torn, fabricated or unreadable, or the coupon owner has already participated in the study.

Your participation is voluntary and anonymous.

If you wish to participate, please come to {insert address} as soon as possible on {enter days of week of study} from {insert start time} until {insert end time}.

If you want more information about the study you can call {insert phone number}.

APPENDIX 2: INSTRUCTIONS FOR PEER RECRUITMENT IN RDS FOR TW

Dear Participant,

We are hoping you will assist us with this study by recruiting your peers. You will be given up to 3 coupons to recruit your peers.

The coupons are uniquely numbered so we can know who is recruited by you and so we can provide you with compensation for each person you recruit. Compensation will only be given if participants are eligible, consent to participate, and participate fully in the study. For each person you recruit who participates, you will be given the hryvnia amount of $3. Each person you recruit who participates will receive the hryvnia equivalent of $6 for their participation and if space is remaining in the study, they can also receive up to $3 for each participant they recruit and who participates. It is important that you recruit your peers as quickly as possible.

Your peers are eligible if they are:

- 14 years old or older
- Live or spends most of their time in the study area
- Agree to participate in the study
- Have had anal or vaginal sex or have injected drugs/hormones using a needle after someone else has injected drugs/hormones with the same needle
- Consider themselves female but were assigned male at birth

APPENDIX 3: ELIGIBILITY FORM

Location of Study	
Date	
Staff ID Number	
Participant ID	
RDS Coupon Number	
RDS Coupon Number	

Please answer the questions below to determine your eligibility for this study:

Q#	Question	Answer
EL1	Indicate the first letter of your first name in Ukrainian	FIRST LETTER ___
EL2	Indicate the first letter of your mother's name in Ukrainian. If you do not remember or know your mother's name, put "ь"	FIRST LETTER ___
EL3	Indicate the first letter of your father's name in Ukrainian.	FIRST LETTER ___
EL4	Specify your year of birth. For example, if you were born on February 15, 1991. Your year of birth is 1991.	YEAR OF BIRTH _____
EL5	Specify your day of birth. For example, if you were born on February 15, 1991. Your day of birth is 15.	DAY OF BIRTH ____
EL6	How old were you at your last birthday?	# YEARS _____
EL7	Have you ever had sex? By sex, we mean either vaginal sex or anal sex. With vaginal sex, we mean when a penis enters a vagina. With anal sex, we mean when a penis enters a person's anus.	0. NO 1. YES
EL8	Have you ever injected any drug or hormone with a needle that had been used by someone else before you?	0. NO 1. YES
EL9	We are not asking about your address, but would like to know, in which oblast do you live in or spend the most time?	1. CHERKAS'KA OBLAST 2. CHERNIVETS'KA OBLAST 3. CHERNIHIVS'KA OBLAST 4. AUTONOMOUS REPUBLIC OF THE CRIMEA 5. DNIPROPETROVS'KA OBLAST 6. DONETS'KA OBLAST 7. IVANO-FRANKIVS'KA OBLAST

		8. KHARKIVS'KA OBLAST 9. KHERSONS'KA OBLAST 10. KHMELNYTSKY OBLAST 11. KIROVOHRAD OBLAST 12. KYIVSKA OBLAST 13. KYIV CITY 14. LUHANS'KA OBLAST 15. LVIVS'KA OBLAST 16. MYKOLAIVS'KA OBLAST 17. ODES'KA OBLAST 18. POLTAVS'KA OBLAST 19. RIVNENS'KA OBLAST 20. SEVASTOPOL 21. SUMS'KA OBLAST 22. TERNOPILS'KA OBLAST 23. VOLYNS'KA OBLAST 24. VINNYTS'KA OBLAST 25. ZAKARPATS'KA OBLAST 26. ZAPORIZ'KA OBLAST 27. ZHYTOMYRS'KA OBLAST
EL10	Which town/city do you live in or spend the most time?	1. _____ 7. DON'T KNOW 8. REFUSE TO ANSWER
EL11	In which neighborhood do you currently live or spend the most time?	1. _____ 7. DON'T KNOW 8. REFUSE TO ANSWER
EL12	How many years have you lived in your answer to EL10? WRITE 0 IF LESS THAN ONE YEAR	# YEARS _____ 997. DON'T KNOW 998. REFUSE TO ANSWER
EL13	What sex were you assigned at birth?	1. MALE 2. FEMALE
EL14	Which gender do you consider yourself?	1. MALE 2. FEMALE 3. NEITHER MALE NOR FEMALE
EL15	Have you participated in this survey between {insert start date of study} and today?	1. YES 2. NO

IT WAS DETERMINED THAT THIS POTENTIAL PARTICIPANT IS:

1. ELIGIBLE
2. INELIGIBLE

SIGNATURE OF FIELD STAFF MEMBER _____

APPENDIX 4: INFORMED CONSENT FORM FOR TW

Location of Study	
Date	
Staff ID Number	
Participant ID	

Study Name: Bio-behavioral Survey of Transgender Men and Transgender Women in Ukraine

We are requesting your participation in this study. The study is being conducted by {insert tender winner} on behalf of the PHC. You were recruited by your peer who also participated in this study and made a decision to give you a recruitment coupon. All components of the study will take about 1.5-3 hours of your time. Taking part in this study is voluntary.

Purpose

The purpose of this study is to understand the behavior, knowledge, attitudes, and experiences of transgender people in the context of HIV/AIDS. The result of the study will be used to evaluate the effectiveness of prevention and treatment programs among transgender people.

What Happens In This Research Study

You will be one of about 1,000 individuals who are in this study. The study is being implemented in 3 oblasts in Ukraine and yours is one of them. The study has these components: a short face-to-face interview, an interview you will complete on your own using a tablet, pre-test-counseling, tests for HIV, hepatitis B, hepatitis C, and syphilis, and post-test counseling.

During the interview, you will be asked questions about your sexual behavior, drug use experiences, participation in the prevention and treatment programs, HIV-testing experience, etc.

The testing will be done using a microtainer tube to draw a small amount of blood from finger prick. If result of the HIV rapid test will be positive, we will do another HIV rapid test to confirm the result. In case the tests are different, we will conduct a third rapid rest. If two of these tests are positive, we will take a small sample of blood to determine if it was recent or long-term HIV-infection and measure the VL level in the blood through additional lab analysis. In case of HIV-positive result the medical worker, will help you enroll in care and start treatment if you are ready.

Before starting the interview, you will have the opportunity to ask questions to the field staff and have them answered.

Risks and Discomforts

You can skip or not answer some question that you do not want to answer. We do not anticipate any risks to people in this study.

Potential Benefits
You will not receive any benefit from being in this study. However, the information you provide will be helpful to better plan HIV programs in Ukraine.

Alternatives

Your alternative is to not participate in the study. If you choose not to participate, you will be able to receive any HIV services that are now available to you. No services, nor access to services, will be taken away from you whether you choose to participate or not.

Subject Costs and Payments

Payments: You will be compensated equivalent of $6 in UAH in cash for your time and travel cost required for completing the interview. You will receive additional compensation for recruitment of your peers, $3 for each eligible peer. The instructions about recruitment you will receive after your participation in the study from field staff.

Subject Costs: It will not cost you any money to be in the study.

Confidentiality

All interviews are anonymous. They will be digitally recorded but will include only your participant ID (not your name) in them. Paper records are kept locked up and electronic datasets are in password protected computers. The data will not have your name. Only the research team will have access to the data. Information from your interview will be used only for research purpose. We will not have your name in any reports or publications.

Subject's Rights

If you agree to be in this study, you do not lose any of your legal rights. Giving your verbal consent means you have heard or have read the information about this study and that you agree to participate.

All research with people is reviewed by a committee that works to protect your rights. If you have questions or concerns about your rights as a study participant, you can call the {title} of the study, {name} anonymously at {phone number}.

Right to Refuse or Withdraw

To be in this study is voluntary. You have the right to choose not to be in this study. If you decide to be in the study and then change your mind, you can withdraw from the research. If you choose to take part in the interview, you have the right to stop at any time.

Giving verbal consent means that you have read this form (or someone has read it to you), we answered all your questions and you voluntarily agree to be in this study. You will receive a copy of this consent form.

Do you give your verbal consent to participate in this study?

YES NO

_____

Person Obtaining Consent (Signature and Printed Name) Date Time

APPENDIX 5: INFORMED CONSENT FORM FOR TM

Location of Study	
Date	
Staff ID Number	
Participant ID	

Study Name: Bio-behavioral Survey of Transgender Men and Transgender Women in Ukraine

We are requesting your participation in this study. The study is being conducted by {insert tender winner} on behalf of the Center for Public Health. You were recruited by your peer who also participated in this study and made a decision to give you a recruitment coupon. All components of the study will take about 1.5-3 hours of your time. Taking part in this study is voluntary.

Purpose

The purpose of this study is to understand the behavior, knowledge, attitudes, and experiences of transgender people in the context of HIV/AIDS. The result of the study will be used to evaluate the effectiveness of prevention and treatment programs among transgender people.

What Happens In This Research Study

You will be one of about 1,000 individuals who are in this study. The study is being implemented in 3 oblasts in Ukraine and yours is one of them. The study has these components: a short face-to-face interview, an interview you will complete on your own using a tablet, pre-test-counseling, tests for HIV, hepatitis B, hepatitis C, and syphilis, and post-test counseling.

During the interview, you will be asked questions about your sexual behavior, drug use experiences, participation in the prevention and treatment programs, HIV-testing experience, etc.

The testing will be done using a microtainer tube to draw a small amount of blood from finger prick. If result of the HIV rapid test will be positive, we will do another HIV rapid test to confirm the result. In case the tests are different, we will conduct a third rapid rest. If two of these tests are positive, we will take a small sample of blood to determine if it was recent or long-term HIV-infection and measure the VL level in the blood through additional lab analysis. In case of HIV-positive result the medical worker, will help you enroll in care and start treatment if you are ready.

Before starting the interview, you will have the opportunity to ask questions to the field staff and have them answered.

Risks and Discomforts

You can skip or not answer some question that you do not want to answer. We do not anticipate any risks to people in this study.

Potential Benefits
You will not receive any benefit from being in this study. However, the information you provide will be helpful to better plan HIV programs in Ukraine.

Alternatives

Your alternative is to not participate in the study. If you choose not to participate, you will be able to receive any HIV services that are now available to you. No services, nor access to services, will be taken away from you whether you choose to participate or not.

Subject Costs and Payments

Payments: You will be compensated equivalent of $6 in UAH in cash for your time and travel cost required for completing the interview.

Subject Costs: It will not cost you any money to be in the study.

Confidentiality

All interviews are anonymous. They will be digitally recorded but will include only your participant ID (not your name) in them. Paper records are kept locked up and electronic datasets are in password protected computers. The data will not have your name. Only the research team will have access to the data. Information from your interview will be used only for research purposeS. We will not have your name in any reports or publications.

Subject's Rights

If you agree to be in this study, you do not lose any of your legal rights. Giving your verbal consent means you have heard or have read the information about this study and that you agree to participate.

All research with people is reviewed by a committee that works to protect your rights. If you have questions or concerns about your rights as a study participant, you can call the {title} of the study, {name} anonymously at {phone number}.

Right to Refuse or Withdraw

To be in this study is voluntary. You have the right to choose not to be in this study. If you decide to be in the study and then change your mind, you can withdraw from the research. If you choose to take part in the interview, you have the right to stop at any time.

Giving verbal consent means that you have read this form (or someone has read it to you), we answered all your questions and you voluntarily agree to be in this study. You will receive a copy of this consent form.

Do you give your verbal consent to participate in this study?

YES NO

_____

Person Obtaining Consent (Signature and Printed Name) Date Time

APPENDIX 6: SURVEY INSTRUMENT

SEE SEPARATE FILE

APPENDIX 7: TESTING RESULTS FORM

TRF1	Location of Study	
TRF2	Date	
TRF3	Staff ID Number	
TRF4	Participant ID	
TRF5	Time of Testing	
TRF6	What is your current HIV status?	0. NEGATIVE 1. POSITIVE 2. I DON'T KNOW
TRF7	IF RESPONDENT ANSWERS '0' OR '2' SKIP TO TRF10	
TRF8	Are you registered in HIV/AIDS Clinic as a PLHIV?	0. NO 1. YES 2. I DON'T KNOW
TRF9	Are you currently taking ART?	0. NO 1. YES 2. I DON'T KNOW
TRF10	PRE-TEST COUNSELING	
TRF9	Hep B Result	0. NEGATIVE 1. POSITIVE 2. INCONCLUSIVE
TRF10	Hep C Result	0. NEGATIVE 1. POSITIVE 2. INCONCLUSIVE
TRF11	Syphilis Result	0. NEGATIVE 1. POSITIVE 2. INCONCLUSIVE
TRF12	HIV Rapid Test 1	0. NEGATIVE 1. POSITIVE 2. INCONCLUSIVE
TRF13	IF TRF12 IS '0' SKIP TO TRF22	
TRF14	HIV Rapid Test 2	0. NEGATIVE 1. POSITIVE 2. INCONCLUSIVE
TRF15	IF TRF12 AND TRF14 ARE BOTH '1' SKIP TO TRF18	
TRF16	HIV Rapid Test 3	0. NEGATIVE 1. POSITIVE

		2. INCONCLUSIVE
TRF17	IF 2 OF 3 OF THE RAPID TESTS HAVE NEGATIVE RESULTS, SKIP TO TRF22	
TRF18	DBS PREPARATION	0. NOT TAKEN 1. TAKEN
TRF19	REFERRAL TO HIV/AIDS CENTER	0. NOT COMPLETED 1. COMPLETED 2. NOT SURE
TRF20	HAS PATIENT VISITED HIV/AIDS CENTER FOR ENROLLMENT IN CARE?	0. NO 1. YES 2. NOT SURE
TRF21	WAS PATIENT ENROLLED IN CARE AT THE HIV/AIDS CENTER?	0. NO 1. YES 2. NOT SURE
TRF22	POST-TEST COUNSELING	
TRF23	Participant ID	

APPENDIX 8: INFORMED CONSENT FORM FOR KEY INFORMANT INTERVIEWS OF TW

Study Name: Bio-behavioral Survey of Transgender Men and Transgender Women in Ukraine

Hello, my name is [researcher's name]. I'm asking you to participate in the formative assessment, which is held by {insert tender winner} as the preparation stage for the "Monitoring of Behavior and HIV-infection Prevalence Among Transgender People in Ukraine"

The main objectives of this assessment are: Determine seed selection criteria for the RDS sampling of transgender women; Determine study sites for RDS sampling of transgender women

Procedures, Privacy, and Confidentiality

The interview will last approximately 45 minutes. During the interview, you will be asked about your expertise and opinions on transgender women. If you agree to participate, we will protect your privacy. No identifying information will be kept in the file containing your responses from this interview. This helps ensure your name will not be used in any reports.

Potential Risks and Discomforts and Right to Refuse

We would not ask you about any personal information. Participating in this interview is voluntary. You can decide not to answer questions or to stop the interview at any time.

Anticipated Benefits

Your answers will help us to plan and prepare for the study and its results will used for outreach activities, planning, monitoring and evaluation of the effectiveness of HIV prevention, treatment, care and support programs among transgender women.

Identification of Investigators

All research with people is reviewed by a committee that works to protect your rights. If you have questions or concerns about your rights as a study participant, you can call the {title} of the study, {name} anonymously at {phone number}.

Subject's Rights

If you agree to be in this study, you do not lose any of your legal rights. This consent form means that you have heard or have read the information about this study and that you agree to participate.

Participation and Withdrawal

To be in this study is voluntary. You have the right to choose not to be in this study. If you decide to be in the study and then change your mind, you can withdraw from the research. If you choose to take part in the interview, you have the right to stop at any time.

Do you give your verbal consent to participate in this study?

YES NO

Person Obtaining Consent (Signature and Printed Name) Date Time

APPENDIX 9: INFORMED CONSENT FOR QUESTIONNAIRE PILOTING

Study Name: Bio-behavioral Survey of Transgender Men and Transgender Women in Ukraine

Hello, my name is [researcher's name]. I'm asking you to participate in the formative assessment, which is held by {insert tender winner} as the preparation stage for the "Monitoring of Behavior and HIV-infection Prevalence Among Transgender People in Ukraine" Now we are in the preparation stage for this study and ask you to participate in the survey with purpose of piloting the questionnaire.

We are going to ask you questions to receive not only your responses to those questions but also your feedback and comments about questions' wording, their unambiguous, and the response options.

Procedures, Privacy, and Confidentiality

The interviews will last approximately 60 minutes. During the interview, you will be asked the questions about your sexual behavior, experience of drug usage, participation in the prevention programs, HIV testing, etc. If you agree to participate, we will protect your privacy. No identifying information will be recoded. All interviews are anonymous. Paper records are kept locked and will be used only with the purpose to improve the questionnaire before its use in the study.

Potential Risks and Discomforts and Right to Refuse

The data will not have your name or other identifiable information. Participating in this interview is voluntary. You can decide not to answer questions or to stop the interview at any time.

Anticipated Benefits

You will not receive any benefit from being in this study. Your answers will help us to prepare the study and to develop the questionnaire to be correctly understood by people like you.

Alternatives

Your alternative is not to participate in the study. If you choose not to participate, you will be able to receive any HIV services that are now available to you. No services, nor access to services, will be taken away from you whether they choose to participate or not.

Subject Costs and Payments

Payments: You will be compensated equivalent of $6 in UAH in cash for your time and travel cost required for completing the interview.

Subject Costs: It will not cost you any money to be in the study.

Identification of Investigators

All research with people is reviewed by a committee that works to protect your rights. If you have questions or concerns about your rights as a study participant, you can call the {title} of the study, {name} anonymously at {phone number}.

Subject's Rights

If you agree to be in this study, you do not lose any of your legal rights. This consent form means that you have heard or have read the information about this study and that you agree to participate.

Participation and Withdrawal

To be in this study is voluntary. You have the right to choose not to be in this study. If you decide to be in the study and then change your mind, you can withdraw from the research. If you choose to take part in the interview, you have the right to stop at any time.

Do you give your verbal consent to participate in this study?

YES NO

_____

Person Obtaining Consent (Signature and Printed Name) Date Time

APPENDIX 10: DATA USE AND CONFIDENTIALITY AGREEMENT

PLEASE COMPLETE THE FOLLOWING ITEMS

NAME	
INSTITUTION	
PROJECT TITLE	Bio-behavioral Survey of Transgender Men and Transgender Women in Ukraine
ROLE WITHIN THE PROJECT	

The information obtained in the study is of a highly confidential nature and has been given by the study participants on the understanding that it will be treated in the strictest confidence. Failure to agree to these rules will result in your inability to work on this study.

Please initial each point and sign at the bottom to indicate that you will abide by these rules:

1) I will not try to identify study participants.	
2) I have understood the data security and confidentiality issues and will adhere to them for the duration of this project.	
3) I will not share any data with any researchers other than those working on this research project who have also signed a copy of this form.	
4) I will not use or disclose “data set” or “information” for any purpose other than the Research Project identified below, or as required by law	
5) I will not distribute any part of the dataset to anyone who is not part of the research team, unless required by law.	
6) I agree not to attempt to re-identify the source of any information provided.	
7) I understand that I am required to securely store all data (paper forms or electronic databases) available for me.	

Failure to abide by these rules will result in exclusion of you from further access to data and you will be subject to all appropriate sanctions including criminal sanctions, where applicable.

PRINTED NAME	
SIGNATURE	
DATE	

APPENDIX 11: ADVERSE EVENT FORM

FILL OUT THIS FORM WITHIN 24 HOURS OF THE EVENT AND SEND TO THE RESEARCH TEAM

STAFF NAME	
STAFF ID NUMBER	
DATE OF ADVERSE EVENT	
CITY OF ADVERSE EVENT	
PARTICIPANT ID	
AGE OF PARTICIPANT	
GENDER OF PARTICIPANT	TRANSGENDER WOMAN TRANSGENDER MAN
OUTCOME OF ADVERSE EVENT	❑ ONGOING AT THIS TIME ❑ RESOLVED WITH NO CONSEQUENCES ❑ RESOLVE WITH CONSEQUENCES ❑ DEATH ❑ PRESENT AT DEATH BUT NOT CONTRIBUTING TO DEATH
DATE OF RESOLUTION	❑ _____ ❑ ONGOING
SERIOUSNESS CRITERIA	❑ LIFE-THREATENING ❑ REQUIRED HOSPITALIZATION ❑ DISABLING/INCAPACITATING ❑ IMPORTANT MEDICAL EVENT ❑ IMPORTANT NON-MEDICAL EVENT ❑ FATAL ❑ DATE OF DEATH _____ ❑ PRIMARY CAUSE OF DEATH _____
RELATIONSHIP TO STUDY	❑ RELATED (ASSOCIATED WITH PARTICIPATION IN THE STUDY. THERE IS REASONABLE POSSIBILITY THAT THE EXPERIENCE MAY HAVE BEEN CAUSED BY THE STUDY) ❑ UNRELATED
IF ADVERSE EFFECT IS UNRELATED PLEASE SELECT POSSIBLE REASONS	❑ CONCURRENT ILLNESS, DISEASE, OR OTHER EXTERNAL FACTORS, SPECIFY: ❑ CONCURRENT MEDICATION, SPECIFY: ❑ SECONDARY STUDY PROCEDURE, SPECIFY: ❑ ACCIDENT, TRAUMA, OR OTHER EXTERNAL FACTORS, SPECIFY: ❑ OTHER, SPECIFY:
CONTINUE WITH NARRATIVE ON THE BACK OF THIS PAGE	

NARRATIVE/COMMENTS PROVIDE A DESCRIPTION OF THE ADVERSE EVENTS INCLUDING CHRONOLOGICAL CLINICAL PRESENTATION AND EVOLUTION OF THE ADVERSE EVENT AND ASSOCIATE SIGNS/SYMPTOMS
IF ADDITIONAL SPACE IS NEEDED, PLEASE ATTACH ADDITIONAL PAGES.

DATE OF SUBMISSION TO RESEARCH TEAM	
NAME OF REPORTING FIELD STAFF	

SIGNATURE OF REPORTING FIELD STAFF	

APPENDIX 12: PROTOCOL DEVIATION FORM

FILL OUT THIS FORM WITHIN 24 HOURS OF THE EVENT AND SEND TO THE RESEARCH TEAM

STAFF NAME	
STAFF ID NUMBER	
DATE OF DEVIATION	
DATE DEVIATION WAS IDENTIFIED	
CITY OF DEVIATION	
PARTICIPANT ID	
DEVIATION WAS IDENTIFIED BY:	
TYPE OF DEVIATION	❑ CONSENT PROCEDURES ❑ INCLUSION/EXCLUSION CRITERIA ❑ STUDY PROCEDURES ❑ ALGORITHM OF STUDY ❑ LABORATORY TESTING PROCEDURES ❑ ADVERSE EVENT REPORTING ❑ DATA USE AND DISSEMINATION
DESCRIPTION OF DEVIATION	
DID THE PARTICIPANT CONTINUE IN THE STUDY?	❑ YES ❑ NO
DOES THE DEVIATION MEET IRB REPORTING REQUIREMENTS?	❑ YES ❑ NO
DATE THE DEVIATION WAS REPORTED TO THE IRB	
ACTION TAKEN TO RESOLVE (IF ANY)	
ADDITIONAL COMMENTS	

DATE OF SUBMISSION TO RESEARCH TEAM	

NAME OF REPORTING FIELD STAFF	
SIGNATURE OF REPORTING FIELD STAFF	

APPENDIX 13: STANDARD OPERATING PROCEDURES FOR SAMPLE COLLECTIONS

APPENDIX 14: EXAMPLE DATA ANALYSIS TABLES

TABLE 1: TRANSGENDER PEOPLE

INDICATOR	TM	TM <25	TM >25	TW	TW <25	TW >25	TP	TP <25	TP >25
Number of participants									
Number who reported they are living with HIV									
Percentage living with HIV									
Number who test positive for HIV									
Number tested for HIV									
Percentage who tested for HIV in the past 12 months or know their current HIV status									
Number who have tested and whose result is positive									
Number who have tested and whose result is negative									
Number who know their HIV status									
Number who answered the question “Do you know your HIV status from an HIV test?”									
Percentage living with HIV who report receiving ART in the past 12 months									
Number living with HIV who report receiving ART in the past 12 months									
Percentage reporting using a condom during their most recent sexual intercourse									
Number who reported using a condom during their most recent sexual intercourse									
Percentage who reported being given condoms and lubricant in the past three months									
Number who reported being given condoms and lubricant in the past three months									
Number who responded to questions about being given condoms and lubricant in the past three months									
Percentage who reported receiving									

counseling on condom use and safer sex in the past three months									
Number who reported receiving counseling on condom use and safer sex in the past three months									
Number who responded to the question about receiving counseling on condom use and safer sex in the past three months									
Percentage who reported having been tested for STIs in the past three months									
Number who reported having been tested for STIs in the past three months									
Number who responded to questions about having been tested for STIs in the past three months									
Percentage who reported receiving at least two of the above-mentioned HIV prevention services.									
Number who reported receiving at least two of the above-mentioned HIV prevention services.									
Number who responded to at least two of the question sets used to determine their use of HIV-prevention services									
Percentage who tested positive for hepatitis B and tested positive for HIV									
Number who tested positive for hepatitis B and tested positive for HIV									
Number who tested for both hepatitis B and HIV									
Percentage who tested positive for hepatitis C and tested positive for HIV									
Number who tested positive for hepatitis C and tested positive for HIV									
Number who tested for both hepatitis C and HIV									
Percentage who reported they									

avoided seeking HIV testing in the last 6 months									
Number who reported they avoided seeking HIV testing in the last 6 months									
Number who reported not having tested for HIV in the last 6 months									
Percentage who reported they were living with HIV and reported they avoided receiving HIV medical care in the last 6 months									
Number who reported they were living with HIV and reported they avoided receiving HIV medical care in the last 6 months									
Number who reported they were living with HIV and reported they never received or having stopped receiving HIV medical care									
Percentage who reported they were living with HIV and reported they avoided seeking HIV treatment in the last 6 months									
Number who reported they were living with HIV and reported they avoided seeking HIV treatment in the last 6 months									
Number who reported they were living with HIV and reported never having taken or having stopped taking HIV treatment									
Percentage who reported living with HIV and reported having experienced stigma and discrimination in HIV-related healthcare services in the past 6 months									
Number of people who responded yes to at least one of the stigma and discrimination in HIV-related healthcare services questions									
Number who responded to at least one of the stigma and discrimination in HIV-related healthcare services questions									
Percentage who reported living with HIV and reported having experienced stigma and									

discrimination in non-HIV-related healthcare services in the past 6 months									
Number of people who responded yes to at least one of the stigma and discrimination in non-HIV-related healthcare services questions									
Number who responded to at least one of the stigma and discrimination in non-HIV-related healthcare services questions									

TABLE 2: TRANSGENDER PEOPLE WHO ARE CSW

INDICATOR	TM	TM <25	TM >25	TW	TW <25	TW >25	TP	TP <25	TP >25
Number of CSW									
Number of CSW who reported living with HIV									
Percentage of CSW living with HIV									
Number of CSW who test positive for HIV									
Number of CSW tested for HIV									
Percentage of CSW who tested for HIV in the past 12 months or know their current HIV status									
Number of CSW who have tested and whose result is positive									
Number of CSW who have tested and whose result is negative									
Number of CSW who know their HIV status									
Number of CSW who answered the question “Do you know your HIV status from an HIV test?”									
Percentage of CSW living with HIV who report receiving ART in the past 12 months									
Number of CSW living with HIV who report receiving ART in the past 12 months									
Percentage of CSW reporting using a condom with their most recent client									

Number of CSW who reported using a condom with their most recent client									
Number of CSW who reported having commercial sex in the past 12 months									
Percentage of CSW who reported being given condoms and lubricant in the past three months									
Number of CSW who reported being given condoms and lubricant in the past three months									
Number of CSW who responded to questions about being given condoms and lubricant in the past three months									
Percentage of CSW who reported receiving counseling on condom use and safer sex in the past three months									
Number of CSW who reported receiving counseling on condom use and safer sex in the past three months									
Number of CSW who responded to the question about receiving counseling on condom use and safer sex in the past three months									
Percentage of CSW who reported having been tested for STIs in the past three months									
Number of CSW who reported having been tested for STIs in the past three months									
Number of CSW who responded to questions about having been tested for STIs in the past three months									
Percentage of CSW who reported receiving at least two of the above-mentioned HIV prevention services.									
Number of CSW who reported receiving at least two of the above-mentioned HIV prevention services.									
Number of CSW who responded to at least two of the question sets used to determine their use of HIV-prevention services									

Percentage of CSW with active syphilis									
Number of CSW who tested positive for active syphilis									
Number of CSW who were tested for active syphilis									
Percentage of CSW who reported they avoided seeking healthcare in the last 6 months									
Number of CSW who reported they avoided seeking healthcare in the last 6 months									
Number of CSW who answered the question about having avoided seeking healthcare in the last 6 months									
Percentage of CSW who reported they avoided seeking HIV testing in the last 6 months									
Number of CSW who reported they avoided seeking HIV testing in the last 6 months									
Number of CSW who answered the question about having avoided seeking HIV testing in the last 6 months									
Percentage of CSW who reported they were living with HIV and reported they avoided receiving HIV medical care in the last 6 months									
Number of CSW who reported they were living with HIV and reported they avoided receiving HIV medical care in the last 6 months									
Number of CSW who reported they were living with HIV and reported they never received or having stopped receiving HIV medical care									
Percentage of CSW who reported they were living with HIV and reported they avoided seeking HIV treatment in the last 6 months									
Number of CSW who reported they were living with HIV and reported they avoided seeking HIV treatment in the last 6 months									

Number of CSW who reported they were living with HIV and reported never having taken or having stopped taking HIV treatment									

TABLE 3: TRANSGENDER PEOPLE WHO ARE PWID

INDICATOR	TM	TM <25	TM >25	TW	TW <25	TW >25	TP	TP <25	TP >25
Number of PWID									
Number of PWID who reported living with HIV									
Percentage of PWID living with HIV									
Number of PWID who test positive for HIV									
Number of PWID tested for HIV									
Percentage of PWID who tested for HIV in the past 12 months or know their current HIV status									
Number of PWID who have tested and whose result is positive									
Number of PWID who have tested and whose result is negative									
Number of PWID who know their HIV status									
Number of PWID who answered the question “Do you know your HIV status from an HIV test?”									
Percentage of PWID living with HIV who report receiving ART in the past 12 months									
Number of PWID living with HIV who report receiving ART in the past 12 months									
Percentage of PWID reporting using a condom the last time they had sexual intercourse									
Number of PWID who reported using a condom the last time they had sexual intercourse									
Number of PWID who reported having had sexual intercourse in the past month									
Percentage of PWID who reported									

being given condoms and lubricant in the past three months									
Number of PWID who reported being given condoms and lubricant in the past three months									
Number of PWID who responded to questions about being given condoms and lubricant in the past three months									
Percentage of PWID who reported receiving counseling on condom use and safer sex in the past three months									
Number of PWID who reported receiving counseling on condom use and safer sex in the past three months									
Number of PWID who responded to the question about receiving counseling on condom use and safer sex in the past three months									
Percentage of PWID who reported receiving new, clean needles or syringes in the past three months									
Number of PWID who reported receiving new, clean needles or syringes in the past three months									
Number of PWID who responded to the question about receiving new, clean needles or syringes in the past three months									
Percentage of PWID who reported receiving at least two of the above-mentioned HIV prevention services									
Number of PWID who reported receiving at least two of the above-mentioned HIV prevention services.									
Number of PWID who responded to at least two of the question sets used to determine their use of HIV-prevention services									
Percentage of PWID reporting the use of sterile injecting equipment the last time they injected									
Number of PWID reporting the use of sterile injecting equipment the last time they injected									

Number of PWID who reported injecting drugs in the past month									
Percentage of PWID reporting receiving opioid substitution therapy									
Number of PWID reporting receiving opioid substitution therapy at specified date									
Percentage of PWID who tested positive for hepatitis B and tested positive for HIV									
Number of PWID who tested positive for hepatitis B and tested positive for HIV									
Number of PWID who tested for both hepatitis B and HIV									
Percentage of PWID who tested positive for hepatitis C and tested positive for HIV									
Number of PWID who tested positive for hepatitis C and tested positive for HIV									
Number of PWID who tested for both hepatitis C and HIV									
Percentage of PWID who reported they avoided seeking HIV testing in the last 6 months									
Number of PWID who reported they avoided seeking HIV testing in the last 6 months									
Number of PWID who reporting not having tested for HIV in the last 6 months									
Percentage of PWID who reported they were living with HIV and reported they avoided receiving HIV medical care in the last 6 months									
Number of PWID who reported they were living with HIV and reported they avoided receiving HIV medical care in the last 6 months									
Number of PWID who reported they were living with HIV and reported they never received or having stopped receiving HIV medical care									
Percentage of PWID who reported									

they were living with HIV and reported they avoided seeking HIV treatment in the last 6 months									
Number of PWID who reported they were living with HIV and reported they avoided seeking HIV treatment in the last 6 months									
Number of PWID who reported they were living with HIV and reported never having taken or having stopped taking HIV treatment									

TABLE 4: TRANSGENDER PEOPLE WHO REPORTED TAKING PREP IN THE LAST SIX MONTHS

AGE RANGE	TM	TW	TP
ALL			
15-19			
20-24			
25-49			
50+			